Highly diluted medication reduces parasitemia and improves experimental infection evolution by <it>Trypanosoma cruzi</it>
<p>Abstract</p> <p>Background</p> <p>There is no published information about the use of different protocols to administer a highly diluted medication.</p> <p>Evaluate the effect of different protocols for treatment with biotherapic <it>T. cruzi</it&...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2012-07-01
|
Series: | BMC Research Notes |
Subjects: | |
Online Access: | http://www.biomedcentral.com/1756-0500/5/352 |
id |
doaj-077c6fe82a84436da6f791a5751caff7 |
---|---|
record_format |
Article |
spelling |
doaj-077c6fe82a84436da6f791a5751caff72020-11-25T03:28:30ZengBMCBMC Research Notes1756-05002012-07-015135210.1186/1756-0500-5-352Highly diluted medication reduces parasitemia and improves experimental infection evolution by <it>Trypanosoma cruzi</it>Aleixo DeniseFerraz FabianaFerreira Érikade Lana MartaGomes Mônicade Abreu Filho Beníciode Araújo Silvana<p>Abstract</p> <p>Background</p> <p>There is no published information about the use of different protocols to administer a highly diluted medication.</p> <p>Evaluate the effect of different protocols for treatment with biotherapic <it>T. cruzi</it> 17 dH (BIOT<sub><it>Tc</it>17dH</sub>) on clinical/parasitological evolution of mice infected with <it>T. cruzi-Y</it> strain.</p> <p>Methods</p> <p>A blind, randomized controlled trial was performed twice, using 60 28-day-old male Swiss mice infected with <it>T. cruzi-Y</it> strain, in five treatment groups: CI <it>-</it> treated with a 7% ethanol-water solution, diluted in water (10 μL/mL) <it>ad libitum</it>; <it>BIOT</it><sub><it>PI</it></sub> - treated with BIOT<sub><it>Tc</it>17dH</sub> in water (10 μL/mL) <it>ad libitum</it> during a period that started on the day of infection; <it>BIOT</it><sub><it>4DI</it></sub> - treated with BIOT<sub><it>Tc</it>17dH</sub> in water (10 μL/mL) <it>ad libitum</it> beginning on the 4<sup>th</sup> day of infection; <it>BIOT</it><sub><it>4-5–6</it></sub> - treated with BIOT<sub><it>Tc</it>17dH</sub> by gavage (0.2 mL/ animal/day) on the 4<sup>th</sup>, 5<sup>th</sup> and 6<sup>th</sup> days after infection; <it>BIOT</it><sub><it>7-8–9</it></sub> - treated with BIOT<sub><it>Tc</it>17dH</sub> by gavage (0.2 mL/ animal/day) on the 7<sup>th</sup>, 8<sup>th</sup> and 9<sup>th</sup> days after infection. We evaluated: parasitemia; total parasitemia (P<sub>total</sub>); maximum peak of parasites; prepatent period (PPP) - time from infection to detection of the parasite in blood; patent period (PP) - period when the parasitemia can be detected in blood; clinical aspects; and mortality.</p> <p>Results</p> <p>Parasitological parameters in the BIOT<sub>PI</sub> and mainly in the BIOT<sub>4PI</sub> group showed better evolution of the infection compared to the control group (CI), with lower P<sub>total</sub>, lower maximum peak of parasites, higher PPP, lower PP and longer survival times. These animals showed stable body temperature and higher weight gain and water consumption, with more animals having normal-appearing fur for longer periods. In contrast, groups BIOT<sub>4-5–6</sub> and BIOT<sub>7-8–9</sub> showed worse evolution of the infection compared to the control group, considering both parasitological and clinical parameters. The correlation analysis combined with the other data from this study indicated that the prepatent period is the best parameter to evaluate the effect of a medication in this model.</p> <p>Conclusions</p> <p>The BIOT<sub>4DI</sub> group showed the best clinical and parasitological evolution, with lower parasitemia and a trend toward lower mortality and a longer survival period. The prepatent period was the best parameter to evaluate the effect of a medication in this model.</p> http://www.biomedcentral.com/1756-0500/5/352BiotherapyMice infectionParasitological evaluationClinical evaluationPrepatent period |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Aleixo Denise Ferraz Fabiana Ferreira Érika de Lana Marta Gomes Mônica de Abreu Filho Benício de Araújo Silvana |
spellingShingle |
Aleixo Denise Ferraz Fabiana Ferreira Érika de Lana Marta Gomes Mônica de Abreu Filho Benício de Araújo Silvana Highly diluted medication reduces parasitemia and improves experimental infection evolution by <it>Trypanosoma cruzi</it> BMC Research Notes Biotherapy Mice infection Parasitological evaluation Clinical evaluation Prepatent period |
author_facet |
Aleixo Denise Ferraz Fabiana Ferreira Érika de Lana Marta Gomes Mônica de Abreu Filho Benício de Araújo Silvana |
author_sort |
Aleixo Denise |
title |
Highly diluted medication reduces parasitemia and improves experimental infection evolution by <it>Trypanosoma cruzi</it> |
title_short |
Highly diluted medication reduces parasitemia and improves experimental infection evolution by <it>Trypanosoma cruzi</it> |
title_full |
Highly diluted medication reduces parasitemia and improves experimental infection evolution by <it>Trypanosoma cruzi</it> |
title_fullStr |
Highly diluted medication reduces parasitemia and improves experimental infection evolution by <it>Trypanosoma cruzi</it> |
title_full_unstemmed |
Highly diluted medication reduces parasitemia and improves experimental infection evolution by <it>Trypanosoma cruzi</it> |
title_sort |
highly diluted medication reduces parasitemia and improves experimental infection evolution by <it>trypanosoma cruzi</it> |
publisher |
BMC |
series |
BMC Research Notes |
issn |
1756-0500 |
publishDate |
2012-07-01 |
description |
<p>Abstract</p> <p>Background</p> <p>There is no published information about the use of different protocols to administer a highly diluted medication.</p> <p>Evaluate the effect of different protocols for treatment with biotherapic <it>T. cruzi</it> 17 dH (BIOT<sub><it>Tc</it>17dH</sub>) on clinical/parasitological evolution of mice infected with <it>T. cruzi-Y</it> strain.</p> <p>Methods</p> <p>A blind, randomized controlled trial was performed twice, using 60 28-day-old male Swiss mice infected with <it>T. cruzi-Y</it> strain, in five treatment groups: CI <it>-</it> treated with a 7% ethanol-water solution, diluted in water (10 μL/mL) <it>ad libitum</it>; <it>BIOT</it><sub><it>PI</it></sub> - treated with BIOT<sub><it>Tc</it>17dH</sub> in water (10 μL/mL) <it>ad libitum</it> during a period that started on the day of infection; <it>BIOT</it><sub><it>4DI</it></sub> - treated with BIOT<sub><it>Tc</it>17dH</sub> in water (10 μL/mL) <it>ad libitum</it> beginning on the 4<sup>th</sup> day of infection; <it>BIOT</it><sub><it>4-5–6</it></sub> - treated with BIOT<sub><it>Tc</it>17dH</sub> by gavage (0.2 mL/ animal/day) on the 4<sup>th</sup>, 5<sup>th</sup> and 6<sup>th</sup> days after infection; <it>BIOT</it><sub><it>7-8–9</it></sub> - treated with BIOT<sub><it>Tc</it>17dH</sub> by gavage (0.2 mL/ animal/day) on the 7<sup>th</sup>, 8<sup>th</sup> and 9<sup>th</sup> days after infection. We evaluated: parasitemia; total parasitemia (P<sub>total</sub>); maximum peak of parasites; prepatent period (PPP) - time from infection to detection of the parasite in blood; patent period (PP) - period when the parasitemia can be detected in blood; clinical aspects; and mortality.</p> <p>Results</p> <p>Parasitological parameters in the BIOT<sub>PI</sub> and mainly in the BIOT<sub>4PI</sub> group showed better evolution of the infection compared to the control group (CI), with lower P<sub>total</sub>, lower maximum peak of parasites, higher PPP, lower PP and longer survival times. These animals showed stable body temperature and higher weight gain and water consumption, with more animals having normal-appearing fur for longer periods. In contrast, groups BIOT<sub>4-5–6</sub> and BIOT<sub>7-8–9</sub> showed worse evolution of the infection compared to the control group, considering both parasitological and clinical parameters. The correlation analysis combined with the other data from this study indicated that the prepatent period is the best parameter to evaluate the effect of a medication in this model.</p> <p>Conclusions</p> <p>The BIOT<sub>4DI</sub> group showed the best clinical and parasitological evolution, with lower parasitemia and a trend toward lower mortality and a longer survival period. The prepatent period was the best parameter to evaluate the effect of a medication in this model.</p> |
topic |
Biotherapy Mice infection Parasitological evaluation Clinical evaluation Prepatent period |
url |
http://www.biomedcentral.com/1756-0500/5/352 |
work_keys_str_mv |
AT aleixodenise highlydilutedmedicationreducesparasitemiaandimprovesexperimentalinfectionevolutionbyittrypanosomacruziit AT ferrazfabiana highlydilutedmedicationreducesparasitemiaandimprovesexperimentalinfectionevolutionbyittrypanosomacruziit AT ferreiraerika highlydilutedmedicationreducesparasitemiaandimprovesexperimentalinfectionevolutionbyittrypanosomacruziit AT delanamarta highlydilutedmedicationreducesparasitemiaandimprovesexperimentalinfectionevolutionbyittrypanosomacruziit AT gomesmonica highlydilutedmedicationreducesparasitemiaandimprovesexperimentalinfectionevolutionbyittrypanosomacruziit AT deabreufilhobenicio highlydilutedmedicationreducesparasitemiaandimprovesexperimentalinfectionevolutionbyittrypanosomacruziit AT dearaujosilvana highlydilutedmedicationreducesparasitemiaandimprovesexperimentalinfectionevolutionbyittrypanosomacruziit |
_version_ |
1724583832557977600 |